Quantcast

Latest Gene therapy Stories

2014-10-23 08:36:46

GERMANTOWN, Md., Oct. 23, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first data in a study transplanting its neural stem cells in an animal model of Alzheimer's disease was presented at the Congress of Neurological Surgeons Annual Meeting, yesterday, in Boston, MA. In a late-breaking science oral presentation titled, "Peri-hippocampal stem cell transplantation rescues cognitive decline in Alzheimer's disease," Osama N. Kashlan, MD, of the departments of...

2014-10-20 12:30:49

CLEVELAND and COLUMBUS, Ohio, Oct. 20, 2014 /PRNewswire-USNewswire/ -- Data published today in the journal Molecular Therapy demonstrates initial clinical proof of principle of a gene therapy to increase muscle strength and function in Becker muscular dystrophy patients. The paper, titled "A Phase I/IIa Follistatin Gene Therapy Trial for Becker Muscular Dystrophy" describes results of the dose ascending trial to assess safety and efficacy in six patients with Becker muscular...

2014-10-17 16:24:40

DUBLIN, October 17, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qvtm8b/global_gene) has announced the addition of the "Global Gene Therapy Market & Pipeline Insight" [http://www.researchandmarkets.com/research/qvtm8b/global_gene ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) There have been significant advancements in the area of gene therapy in terms of research of new drugs....

2014-10-16 08:30:41

RICHMOND, Calif., Oct. 16, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that Company scientists and clinicians, as well as academic collaborators, were invited speakers at three major scientific meetings in Europe and the United States. Their presentations covered a number of therapeutic uses of Sangamo's novel zinc finger protein (ZFP) technology, but were primarily focused on reviewing the progress of the Company's ZFP Therapeutic(®) program in HIV/AIDS....

2014-09-23 08:29:34

President-Elect of the Society for Cryobiology and Former Cell Therapy Executive Join Leading Clinicians, Developers, and Consultants in the Biobanking, Drug Discovery, and Regenerative Medicine Markets BOTHELL, Wash., Sept. 23, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or...

2014-09-12 23:00:37

The increasing demand for biopharmaceutical products like vaccines and antibodies coupled with strong pipelines for biopharmaceuticals and increasing healthcare expenditure will drive the demand for cell culture products. http://www.marketsandmarkets.com/Market-Reports/cell-culture-market-media-sera-reagents-559.html (PRWEB) September 13, 2014 The “Cell Culture Market by Equipment (Bioreactor, Incubator, Centrifuge), by Reagent (Media, Sera, Growth Factors, Serum Free Media), by...

2014-09-11 16:28:04

New Facility Poised to Accelerate the Research and Development of Personalized Cellular Cancer Therapies PHILADELPHIA, Sept. 11, 2014 /PRNewswire-USNewswire/ -- The University of Pennsylvania today reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia. The CACT will become the epicenter for research using Chimeric Antigen...

2014-09-08 08:29:30

Control of Viral Load During Treatment Interruption of Antiretroviral Therapy Sustained and Ongoing for More than One Year in One Subject and Several Months in Another RICHMOND, Calif., Sept. 8, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating that a single infusion of Sangamo's novel ZFP Therapeutic(®), SB-728-T, resulted in sustained reduction and control of viral load (VL) in the absence of antiretroviral drugs...

2014-08-14 16:26:36

GREENWICH, Conn., Aug. 14, 2014 /PRNewswire/ -- Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD. In connection with the transaction, Lentigen Corporation has been renamed Opus Bio, Inc., and has been...

2014-08-14 16:26:34

BERGISCH GLADBACH, Germany, August 14, 2014 /PRNewswire/ -- Addition of lentiviral gene delivery capabilities complements strategic partnering portfolio. Miltenyi Biotec announced today that it has acquired the lentiviral vector manufacturing business and related assets from US company Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications. The acquisition further strengthens Miltenyi Biotec's portfolio in cell and...


Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related